Translational medicine of the glutamate AMPA receptor

By Tomoyuki MIYAZAKI, Hiroki ABE, Hiroyuki UCHIDA, Takuya TAKAHASHI

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Psychiatric and neurological disorders severely hamper patient’s quality of life. Despite their high unmet needs, the development of diagnostics and therapeutics has only made slow progress. This is due to limited evidence on the biological basis of these disorders in humans. Synapses are essential structural units of neurotransmission, and neuropsychiatric disorders are considered as “synapse diseases”. Thus, a translational approach with synaptic physiology is crucial to tackle these disorders. Among a variety of synapses, excitatory glutamatergic synapses play central roles in neuronal functions. The glutamate,-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) is a principal component of glutamatergic neurotransmission; therefore, it is considered to be a promising translational target. Here, we review the limitations of current diagnostics and therapeutics of neuropsychiatric disorders and advocate the urgent need for the promotion of translational medicine based on the synaptic physiology of AMPAR. Furthermore, we introduce our recent translational approach to these disorders by targeting at AMPARs.

Original languageEnglish
Pages (from-to)1-21
Number of pages21
JournalProceedings of the Japan Academy Series B: Physical and Biological Sciences
Issue number1
Publication statusPublished - 2021


  • AMPA receptor
  • PET probe
  • ednonerpic maleate
  • synapse, synaptic plasticity
  • translational medicine

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'Translational medicine of the glutamate AMPA receptor'. Together they form a unique fingerprint.

Cite this